Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology.
Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · May 10, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help doctors predict the risk of stroke in patients with narrowing of the carotid or vertebral arteries, which are important blood vessels in the brain. By using AI technology, the goal is to identify patients who may be at risk of having a stroke early on, allowing for better preventive care. If successful, this research could lead to a new tool that helps doctors manage and reduce the risk of future strokes in patients, improving overall care for those with cerebrovascular diseases.
To participate in this study, candidates should be patients who are having a specific ultrasound test on their blood vessels. However, those with incomplete medical information or missing test results will not be eligible. The trial is currently recruiting participants of all ages and genders. If you join, you can expect to contribute to important research that could change how strokes are predicted and prevented in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing vascular (carotid/vertebral artery) B-ultrasound
- Exclusion Criteria:
- • Patients with missing clinical data such as medical history, cerebrovascular ultrasound results and biochemical data
About Shanghai Jiao Tong University School Of Medicine
Shanghai Jiao Tong University School of Medicine is a leading academic institution in China, renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, the school leverages its extensive expertise in biomedical sciences and innovative healthcare solutions to conduct rigorous clinical studies aimed at improving patient outcomes. With a focus on collaboration and translational research, the institution fosters partnerships with healthcare providers, industry leaders, and regulatory bodies to ensure the highest standards of scientific integrity and ethical conduct in clinical trials. Through its research initiatives, Shanghai Jiao Tong University School of Medicine strives to contribute significantly to the global medical community and enhance the quality of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Yijun Cheng, Doc
Principal Investigator
Ruijin Hospital
Hanbing Shang, Doc
Principal Investigator
Ruijin Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported